Pimavanserin Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 17 mg, 34 mg, 51 mg

Reference Brands: Nuplazid (USA)

Category: Neurology

Pimavanserin is available in Tablets and strengths such as 17 mg, 34 mg, 51 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Pimavanserin is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Pimavanserin can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Pimavanserin, marketed under the brand name Nuplazid, is an atypical antipsychotic medication approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP) in adults. Unlike typical antipsychotics, pimavanserin does not block dopamine receptors, reducing the risk of worsening motor symptoms in Parkinson’s patients. Instead, it selectively acts as an inverse agonist and antagonist at serotonin 5-HT2A receptors, and to a lesser extent 5-HT2C receptors, which are involved in the pathophysiology of psychotic symptoms in PDP. Pimavanserin is administered orally, providing a convenient route of administration for long-term management. Clinical studies have shown that it effectively reduces the frequency and severity of hallucinations and delusions, improving patients’ quality of life without compromising motor function. Common adverse effects include peripheral edema, confusion, and nausea, but it is generally well tolerated under medical supervision. By targeting serotonergic pathways rather than dopaminergic ones, pimavanserin offers a unique and valuable therapeutic option for managing psychosis in Parkinson’s disease while minimizing the risk of exacerbating Parkinsonian motor symptoms.